News and Press Releases
Santhera Announces Approval in Canada for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Health Canada approved AGAMREE for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older This approval makes AGAMREE the first and only approved therapy for DMD...
Category: Other, Pharmaceutical
Posted: October 3, 2025
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland
Clinigen to Acquire SSI Strategy, Charting a Seamless Path from Clinical Strategy to Global Commercialisation for Biotech Innovators
29 September 2025 -- London, UK -- Clinigen, the global pathfinder accelerating patient access to critical medicines across the lifecycle, today announced it has entered into a definitive agreement to...
Category: Biotechnology, Logistics, Other, Pharmaceutical
Posted: September 29, 2025
Clinigen collaborates with Servier to expand access to specialised oncology and haematology medicines in South Africa
17 March 2025 -- London, UK -- Clinigen, the global speciality pharmaceutical services group, today announced that Equity Pharmaceuticals, part of the Clinigen Group, has entered into a new collaboration...
Category: Drug Delivery, Other, Pharmaceutical
Posted: March 17, 2025
Clinigen Announces Strategic Partnership with Tepsivo
Expanding Client Choice with AI-Powered Pharmacovigilance Solutions 27 January 2025 -- London, UK -- Clinigen, the global specialist pharmaceutical services company, today announced a strategic partnership with Tepsivo, a pioneering...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: January 27, 2025
Er-Kim Announces Exclusive Distribution Agreement with the MEDICE Health Family For Vafseo in Central & Eastern Europe
Collaboration will support access of an alternative treatment to improve the lives of people impacted by anemia caused by chronic kidney disease 14 January 2025 -- Warsaw, Poland -- Er-Kim,...
Category: Drug Delivery, Logistics, Other, Pharmaceutical
Posted: January 14, 2025
Akat Mah. Ebulula Mardin Cad. Maya Meridien İş Merkezi No: 16 Daire: 25 34335 Beşiktaş/İstanbul
CN Bio signs strategic partnership with Primetech Corporation to establish distribution channel for OOC solutions in Japan
Agreement establishes direct distribution channel for customers in Japan, providing local support and expertise Partnership solidifies CN Bio’s presence in Asian markets and supports ongoing global expansion. 14 January 2025...
Category: Biotechnology, Logistics, Other, Pharmaceutical
Posted: January 14, 2025
Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland
AGAMREE® is approved by MHRA for treating Duchenne muscular dystrophy (DMD) in patients 4 years of age and older in UK 14 January 2025 -- Pratteln, Switzerland -- Santhera Pharmaceuticals...
Category: Other, Pharmaceutical
Posted: January 14, 2025
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland
Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group
6 January 2025 -- Pratteln, Switzerland -- Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE (vamorolone) in countries...
Category: Logistics, Manufacturing and Packing, Other, Pharmaceutical
Posted: January 6, 2025
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
China’s National Medical Products Administration (NMPA) approved AGAMREE® for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older This approval makes AGAMREE the first and only...
Category: Other, Pharmaceutical
Posted: December 11, 2024
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland
Santhera Receives Positive Recommendation from NICE for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
AGAMREE® has been recommended by NICE for treating Duchenne muscular dystrophy (DMD) in patients 4 years of age and older in England, Wales and Northern Ireland Santhera will be working...
Category: Drug Discovery, Other, Pharmaceutical
Posted: December 10, 2024
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland
Clinigen appoints Fernando Ballester as Chief Financial Officer
2 July 2024 -- London, UK -- Clinigen, the global pharmaceutical services company, today announces the appointment of Fernando Ballester as chief financial officer (CFO), effective 1 August 2024. Fernando,...
Category: Other, Pharmaceutical
Posted: July 2, 2024
Clinigen acquires boutique market access consultancy Ascenian to accelerate access to lifesaving treatments
6 June 2024 -- London, UK -- Clinigen, the global pharmaceutical services company, today announces the acquisition of Ascenian, a boutique global market access consultancy. Together the combined companies will...
Category: Other, Pharmaceutical
Posted: June 6, 2024
Clinigen boosts senior team with three strategic hires
12 March 2024 -- London, UK -- Clinigen, the global pharmaceutical services company, today announces three strategic appointments to advance its transformation into a world leading pharma services company: Nihad...
Category: Other
Posted: March 12, 2024
Clinigen launches ‘What is Possible?’ campaign to accelerate access to medicines on Rare Disease Day
With over 7,000 rare diseases that impact over 300 million people globally, just 5% of rare diseases have a licensed treatment 29 February 2024 -- London, UK -- Clinigen, the...
Category: Other
Posted: February 29, 2024
